For example, a heart failure patient who begins to show rising levels of kidney injury markers (such as NGAL, KIM-1, cystatin C) or specific fibrosis biomarkers might be identified as entering CRS and managed more aggressively to protect renal function [60,61]. This evidence concerns the gene HAVCR1 and congenital rubella syndrome.